Helen Pasternack

University Hospital Schleswig-Holstein — Germany

Medicine · Health Sciences

8h-index759citations30works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(18), Cancer therapeutics and mechanisms(7), Cancer Immunotherapy and Biomarkers(6), HER2/EGFR in Cancer Research(5), Cancer Genomics and Diagnostics(5)

Publications30 total

Erratum zu: Molekularpathologie des nichtkleinzelligen Lungenkarzinoms: aktuelle und kommende Biomarker
Die Pathologie·2025Open Access
Molekularpathologie des nichtkleinzelligen Lungenkarzinoms: aktuelle und kommende Biomarker
Die Pathologie·2025Open Access
Colorectal adenocarcinoma with clear cell changes: immunohistological and molecular findings in three cases
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin·2024· 2 citedOpen Access
Proteomic analyses identify HK1 and ATP5A to be overexpressed in distant metastases of lung adenocarcinomas compared to matched primary tumors
Scientific Reports·2023· 3 citedOpen Access
Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 4 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 2 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 1 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 4 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 2 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 1 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Data from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Data from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Data from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Data from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Histone Demethylase KDM5C Drives Prostate Cancer Progression by Promoting EMT
Cancers·2022· 20 citedOpen Access
PD-L1 Dependent Immunogenic Landscape in Hot Lung Adenocarcinomas Identified by Transcriptome Analysis
Cancers·2021· 7 citedOpen Access
Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas
Scientific Reports·2021· 3 citedOpen Access
Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion
Clinical Cancer Research·2020· 74 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Sabine Merkelbach‐Bruse(17), Andreas H. Scheel(15), Sebastian Michels(15), Rieke Fischer(15), Jana Fassunke(15), Michaela A. Ihle(15), Carina Heydt(15), Jürgen Wolf(15), Hans‐Ulrich Schildhaus(14), Johannes M. Heuckmann(14), Lukas C. Heukamp(14), Martin Peifer(14), Roman K. Thomas(14), Martin L. Sos(14), Sandra Ortiz‐Cuaran(13), Dennis Plenker(13), llona Dahmen(13), Lynnette Fernandez‐Cuesta(13), Lydia Meder(13), Christine M. Lovly(13)